new Trial Showsโ Promise for Reducingโ Inflammation After Heart Attack with antibodyโ Therapy
BOSTON, MA โ- A randomized โphase 2 trial hasโค demonstrated that antibody-mediated inhibition of LOX-1 (lectin-like oxidized LDLโฃ receptor-1)โข mayโ reduce residual โinflammation in patients following a myocardial infarction (heart attack). The study, detailed in[publicationdetailsโข-[publicationdetails-[publicationdetailsโข-[publicationdetails-not provided in source text], offers โคa potentialโข new therapeutic avenue for improving outcomes in individuals who continue to โคexperience inflammation despite โคstandard treatment.
Myocardial infarction frequentlyโ enough leaves behind lingering inflammation, contributing to adverse cardiac remodeling and increased โคrisk of future events. LOX-1,expressed on โฃvarious cells including endothelial cellsโ and macrophages,plays a key role inโข this inflammatory process โฃby mediating โthe uptake of oxidized LDL cholesterol. Blocking LOX-1 with a monoclonal antibody aims to interrupt โคthis cycle andโฃ promote healing.
The trial involvedโ a cohort of researchers withโ extensive ties to theโค pharmaceutical industry, as disclosed in accompanying conflict-of-interest statements. J.S. reportsโ research grant support from Biotronik, sanofi, Pfizer and Attralus; โคconsulting fees from โBMS, Sanofi and Attralus; and speaker bureau fees from Pfizer, AstraZeneca, Boehringer Ingelheim, Novartis, Bayer, Sanofi, Biotronik, CircleCVi, Takeda,โ amicus โand BMS. E.K.โฃ reports lecture fees โfrom Astellas, Abbott, Amgen, โฃastrazeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lillyโ Japan KK, โฃDaiichi-Sankyo, Menarini, Ono pharmaceutical, Ootsuka Pharmaceutical, MSDโข KK, Takeda Pharmaceutical, โTanabe-Mitsubishi, Bayer and Pfizer; and โคconsulting fees or research fund from Boehringer Ingelheim, bayer, Novo Nordisk, Daiichi-Sankyo,โ Abbott, Ono Pharmaceutical โขand Tanabe-Mitsubishi. โA.Z.โข has received grant support โขfrom Novartis and consulting and/or lectureโฃ fees from AstraZeneca, novartis, boehringer Ingelheim, Amarin, โPfizer, Sanofi, Amgen, Eli lilly and Novo Nordisk.A.G.is aโ former full-time employee of AstraZeneca and current full-time employee and stockholder of Ribocure โขPharmaceuticals. M.L.O.D., D.A.M., M.S.S., J.K., J.-G.P. and S.A.M. are members of the TIMI Study Group and have received research grant support thru Brigham and Women’s Hospital from Abbott, โAmgen, Anthos Therapeutics, AstraZeneca, Boehringer โคIngelheim, Daiichi-Sankyo, โIonis, Marea, Merck, Novartis, Pfizer, Saghmos Therapeutics and Verveโฃ Therapeutics and โขhave received consulting fees Amgen, AMPEL BioSolutions, Anthos Therapeutics, AstraZeneca, Berenโ Therapeutics,โค Boehringer Ingelheim, โDr. Reddy’s Laboratories, Fibrogen, Merck, Moderna, Novo Nordisk, Precision BioSciences and Silence Therapeutics.โฃ B.F. reports grant support from AstraZeneca/Medimmune,โข MedTrace, Ionis and NIH/NHLBI.J.L.-S. reports research grant from AstraZeneca, Bayer/Johnson & Johnson, pfizer and โคAmgen, and has receivedโข speaker honoraria from Menarini. A.A.D.P.F. โฃreports consulting fees from AstraZeneca, Novartis, Boehringer โคIngelheim, Merck Sharp Dohmeโข and Mundipharma. M.T.L. has received research funding through the Massachusetts General โHospital from AstraZeneca, American Heart Association, Ionis, Johnson & Johnson Innovation, MedImmune, National Academy of medicine, National Heart, Lung, and Blood Institute and Risk โคManagement Foundation of the Harvard Medical Institutions. J.A.C.L. reports grant funding from AstraZeneca and Canon Medical Systems. โคM.S.S.โ reports research grant support through Brigham and Women’s Hospital from Abbott,โ Amgen, Anthos Therapeutics, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, ionis,โ Marea, Merck, Novartis, Pfizer, Saghmos Therapeutics and Verve Therapeutics, and has received consulting fees from Amgen, AMPEL BioSolutions, โanthos โขTherapeutics, AstraZeneca, Beren Therapeutics, Boehringer Ingelheim, Dr. Reddy’sโฃ Laboratories, Fibrogen, Merck, Moderna, Novo nordisk, Precision BioSciences and Silence Therapeutics.The othreโ authors declare no competing interests.โ
The phase 2 trial’s findings suggest a potential benefit of LOX-1โ inhibition,paving the way forโฃ larger,phase 3 trials to confirm these โคresults and assess the long-term clinical impact on cardiovascular โoutcomes.โ Further research will be crucial to determine the optimal patientโค populationsโ and treatment strategies for this โnovel โฃapproach.